Prothrombin complex concentrate for non-vitamin K oral anticoagulant reversal: Good enough for now?

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 9, 2014, Pages 1425-1427

  Makris, M ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; PROTHROMBIN COMPLEX; RIVAROXABAN; WARFARIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; DRUG COMBINATION; MORPHOLINE DERIVATIVE; PROTHROMBIN; PROTHROMBIN COMPLEX CONCENTRATES; RECOMBINANT BLOOD CLOTTING FACTOR 9; THIOPHENE DERIVATIVE;

BLEEDING; BLEEDING TENDENCY; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; NOTE; PROTHROMBIN TIME; THROMBOGENICITY; THROMBOSIS; VENOUS THROMBOEMBOLISM; DRUG COMBINATION; FEMALE; MALE;

ANTICOAGULANTS; BLOOD COAGULATION FACTORS; DRUG COMBINATIONS; FACTOR IX; FACTOR VII; FACTOR X; FEMALE; HUMANS; MALE; MORPHOLINES; PROTHROMBIN; THIOPHENES;

EID: 84908500391     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12667     Document Type: Note

References (19)

1. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2006: CD001367.
2. Andersen LV, Vestergaard P, Deichgraeber P, Lindholt JS, Mortensen LS, Frost L. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a metaanalysis. Heart 2008; 98: 1607-13.
3. Landfeld CS, Beyh RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-28.
4. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012; 119: 3016-23.
5. van der Hulle T, Kooiman J, den Dexter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treat- ment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12: 320-8.
6. Makris M, van Veen JJ. Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal? Blood Transfusion 2011; 9: 117-19.
7. Sarode R, Milling TJ, Refaai MA, Mandione A, Schneider A, Durn BL, Goldstein JN. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomised, plasma controlled, phase IIIb study. Circulation 2013; 128: 1234-43.
8. Makris M, van Veen JJ, Tait CR, Mumford AD, Laffan M. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 2013; 160: 35-46.
9. van Veen JJ, Maclean RM, Hampton KK, Laidlaw S, Kitchen S, Toth P, Makris M. Protamine reversal of low molecular weight heparin: clinically effective? Blood Coagul Fibrinolysis 2011; 22: 565-70.
10. Kaatz S, Kouides PA, Garcia DA, Spyropoulos AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, van Cott EM, Ansell J. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87(Suppl. 1): S141-5.
11. Kaatz S, Crowther M. Reversal of target specific oral anticoagulants. J Thromb Thrombolysis 2013; 36: 195-202.
12. Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 2014; 111: 189-98.
13. van Ryn J, Schurer J, Kink-Elband M, Clemens A. Reversal of Dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology 2014; 120: 1429-40.
14. Beyer-Westerndorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, Michalski F, Kohler C, Werth S, Sahin K, Tittl L, Hansel U, Weiss N. Rates, management, and outcome of bleeding complications during rivaroxaban therapy in daily care - results from the Dresden NOAC registry. Blood 2014; 124: 955-62.
15. Schulman S, Kieron C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-4.
16. Levi M, Moore KT, Castillejos CF, Kubitza D, Berkowitz SD, Goldhaber SZ, Raghoebar M, Patel MR, Weitz JI, Levy JH. Comparison of three- and four-factor prothrombin complex concentrates on the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014; 12: 1428-36.
17. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T. A specific antidote for dabigatran: functional and structural characterisation. Blood 2013; 121: 3554-62.
18. Sheffield WP, Lambourne MD, Eltringham-Smith LJ, Bhakta V, Arnold DM, Crowther MA. S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo. J Thromb Haemost 2014; 12: 1110-15.
19. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-53.